| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5369 | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1346 | 2021 |
| Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors S Uyoga, IMO Adetifa, HK Karanja, J Nyagwange, J Tuju, P Wanjiku, ... Science 371 (6524), 79-82, 2021 | 309 | 2021 |
| Targets of antibodies against Plasmodium falciparum–infected erythrocytes in malaria immunity JA Chan, KB Howell, L Reiling, R Ataide, CL Mackintosh, FJI Fowkes, ... The Journal of clinical investigation 122 (9), 3227-3238, 2012 | 259 | 2012 |
| ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice NK Alharbi, E Padron-Regalado, CP Thompson, A Kupke, D Wells, ... Vaccine 35 (30), 3780-3788, 2017 | 175 | 2017 |
| Plasmodium falciparum var gene expression is modified by host immunity GM Warimwe, TM Keane, G Fegan, JN Musyoki, CRJC Newton, A Pain, ... Proceedings of the National Academy of Sciences 106 (51), 21801-21806, 2009 | 173 | 2009 |
| Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure P Bejon, G Warimwe, CL Mackintosh, MJ Mackinnon, SM Kinyanjui, ... Infection and immunity 77 (5), 1917-1923, 2009 | 144 | 2009 |
| Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy V Naranbhai, AVS Hill, SS Abdool Karim, K Naidoo, Q Abdool Karim, ... The Journal of infectious diseases 209 (4), 500-509, 2014 | 143 | 2014 |
| Rift Valley fever: biology and epidemiology D Wright, J Kortekaas, TA Bowden, GM Warimwe Journal of General Virology 100 (8), 1187-1199, 2019 | 138 | 2019 |
| Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever GM Warimwe, J Gesharisha, BV Carr, S Otieno, K Otingah, D Wright, ... Scientific reports 6 (1), 20617, 2016 | 124 | 2016 |
| Haemoglobin C and S role in acquired immunity against Plasmodium falciparum malaria F Verra, J Simpore, GM Warimwe, KK Tetteh, T Howard, FHA Osier, ... PloS one 2 (10), e978, 2007 | 115 | 2007 |
| Systematic literature review of Rift Valley fever virus seroprevalence in livestock, wildlife and humans in Africa from 1968 to 2016 MHA Clark, GM Warimwe, A Di Nardo, NA Lyons, S Gubbins PLoS neglected tropical diseases 12 (7), e0006627, 2018 | 96 | 2018 |
| Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model VJ Munster, D Wells, T Lambe, D Wright, RJ Fischer, T Bushmaker, ... npj Vaccines 2 (1), 28, 2017 | 91 | 2017 |
| Assessing the level and determinants of COVID-19 vaccine confidence in Kenya S Orangi, J Pinchoff, D Mwanga, T Abuya, M Hamaluba, G Warimwe, ... Vaccines 9 (8), 936, 2021 | 90 | 2021 |
| Prognostic indicators of life-threatening malaria are associated with distinct parasite variant antigen profiles GM Warimwe, G Fegan, JN Musyoki, CRJC Newton, M Opiyo, G Githinji, ... Science translational medicine 4 (129), 129ra45-129ra45, 2012 | 86 | 2012 |
| The ratio of monocytes to lymphocytes in peripheral blood correlates with increased susceptibility to clinical malaria in Kenyan children GM Warimwe, LM Murungi, G Kamuyu, GM Nyangweso, J Wambua, ... PloS one 8 (2), e57320, 2013 | 78 | 2013 |
| Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice GM Warimwe, G Lorenzo, E Lopez-Gil, A Reyes-Sandoval, ... Virology journal 10, 1-9, 2013 | 69 | 2013 |
| CLIMB-COVID: continuous integration supporting decentralised sequencing for SARS-CoV-2 genomic surveillance SM Nicholls, R Poplawski, MJ Bull, A Underwood, M Chapman, ... Genome biology 22, 1-21, 2021 | 68 | 2021 |
| COVID-19 transmission dynamics underlying epidemic waves in Kenya SPC Brand, J Ojal, R Aziza, V Were, EA Okiro, IK Kombe, C Mburu, ... Science 374 (6570), 989-994, 2021 | 66 | 2021 |
| A protective monoclonal antibody targets a site of vulnerability on the surface of Rift Valley fever virus ER Allen, SA Krumm, J Raghwani, S Halldorsson, A Elliott, VA Graham, ... Cell Reports 25 (13), 3750-3758. e4, 2018 | 53 | 2018 |
Peter Bull在 ccoex.com 的电子邮件经过验证
